Serum vascular endothelial growth factor A (VEGF) is elevated in patients with ovarian granulosa cell tumor (GCT), and VEGF inhibition by bevacizumab induces apoptosis in GCT in Vitro

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 12, 2011, Pages

  Färkkilä, Anniina ^a   Pihlajoki, Marjut ^a   Tauriala, Hanna ^a   Bützow, Ralf ^a   Leminen, Arto ^a   Unkila Kallio, Leila ^a   Heikinheimo, Markku ^a,b   Anttonen, Mikko ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ENDOSTATIN; VASCULOTROPIN A;

ADULT; APOPTOSIS; ARTICLE; CANCER PATIENT; CELL COUNT; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULOSA CELL TUMOR; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; CELL COUNT; CELL LINE, TUMOR; ENDOSTATINS; FEMALE; GRANULOSA CELL TUMOR; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 83155168437     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1812     Document Type: Article

References (40)

1. Schumer ST, Cannistra SA 2003 Granulosa cell tumor of the ovary. J Clin Oncol 21:1180-1189 (Pubitemid 46594151)
2. Malmström H, Högberg T, Risberg B, Simonsen E 1994 Granulosa cell tumors of the ovary: prognostic factors and outcome. Gynecol Oncol 52:50-55 (Pubitemid 24066852)
3. Fotopoulou C, Savvatis K, Braicu EI, Brink-Spalink V, Darb-Esfahani S, Lichtenegger W, Sehouli J 2010 Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome. Gynecol Oncol 119:285-290
4. Fujimoto T, Sakuragi N, Okuyama K, Fujino T, Yamashita K, Yamashiro S, Shimizu M, Fujimoto S 2001 Histopathological prognostic factors of adult granulosa cell tumors of the ovary. Acta Obstet Gynecol Scand 80:1069-1074 (Pubitemid 33052226)
5. Ferrara N, Gerber HP, LeCouter J 2003 The biology of VEGF and its receptors. Nat Med 9:669-676 (Pubitemid 36749215)
6. Folkman J 2006 Antiangiogenesis in cancer therapy: endostatin and its mechanisms of action. Exp Cell Res 312:594-607 (Pubitemid 43290336)
7. Abdollahi A, Hahnfeldt P, Maercker C, Gröne HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE 2004 Endostatin's antiangiogenic signaling network. Mol Cell 13:649-663 (Pubitemid 38368123)
8. Bono P, Teerenhovi L, Joensuu H 2003 Elevated serum endostatin is associated with poor outcome in patients with non-Hodgkin lymphoma. Cancer 97:2767-2775 (Pubitemid 36605144)
9. Zhao J, Yan F, Ju H, Tang J, Qin J 2004 Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett 204:87-95 (Pubitemid 38117197)
10. Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, Sakahara H, Mori T 1997 Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer 76:1221-1227 (Pubitemid 27448021)
11. Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK 2002 Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 8:3193-3197 (Pubitemid 35155030)
12. Fox SB, Turley H, Cheale M, Blázquez C, Roberts H, James N, Cook N, Harris A, Gatter K 2004 Phosphorylated KDRis expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. J Pathol 202:313-320 (Pubitemid 38325240)
13. Masood R, Cai J, Zheng T, Smith DL, Hinton DR, Gill PS 2001 Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 98:1904-1913
14. Sher I, Adham SA, Petrik J, Coomber BL 2009 Autocrine VEGFA/ KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer 124:553-561
15. Färkkilä A, Anttonen M, Pociuviene J, Leminen A, Butzow R, Heikinheimo M, Unkila-Kallio L 2011 Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors. Eur J Endocrinol 164:115-122
16. Jubb AM, Harris AL 2010 Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11:1172-1183
17. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM 2010 Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 28:154-159
18. Tao X, Sood AK, Deavers MT, Schmeler KM, Nick AM, Coleman RL, Milojevic L, Gershenson DM, Brown J 2009 Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 114:431-436
19. Kesterson JP, Mhawech-Fauceglia P, Lele S 2008 The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report. Gynecol Oncol 111: 527-529
20. Anttonen M, Unkila-Kallio L, Leminen A, Butzow R, Heikinheimo M 2005 High GATA-4 expression associates with aggressive behavior, whereas low anti-Mullerian hormone expression associates with growth potential of ovarian granulosa cell tumors. J Clin Endocrinol Metab 90:6529-6535 (Pubitemid 41759309)
21. Greenaway J, Connor K, Pedersen HG, Coomber BL, LaMarre J, Petrik J 2004 Vascular endothelial growth factor and its receptor, Flk-1/KDR, are cytoprotective in the extravascular compartment of the ovarian follicle. Endocrinology 145:2896-2905 (Pubitemid 38686239)
22. Nishi Y, Yanase T, Mu Y, Oba K, Ichino I, Saito M, Nomura M, Mukasa C, Okabe T, Goto K, Takayanagi R, Kashimura Y, Haji M, Nawata H 2001 Establishment and characterization of a steroido-genic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor. Endocrinology 142:437-445 (Pubitemid 32183706)
23. Kyrönlahti A, Kauppinen M, Lind E, Unkila-Kallio L, Butzow R, Klefström J, Wilson DB, Anttonen M, Heikinheimo M 2010 GATA4 protects granulosa cell tumors from TRAIL-induced apoptosis. Endocr Relat Cancer 17:709-717
24. Jamieson S, Butzow R, Andersson N, Alexiadis M, Unkila-Kallio L, Heikinheimo M, Fuller PJ, Anttonen M 2010 The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Mod Pathol 23:1477-1485
25. Emlet DR, Brown KA, Kociban DL, Pollice AA, Smith CA, Ong BB, Shackney SE 2007 Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther 6:2664-2674 (Pubitemid 350058147)
26. Sims TL, Williams RF, Ng CY, Rosati SF, Spence Y, Davidoff AM 2008 Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease. Surgery 144:269-275 (Pubitemid 352010323)
27. Kyrönlahti A, Rämö M, Tamminen M, Unkila-Kallio L, Butzow R, Leminen A, Nemer M, Rahman N, Huhtaniemi I, Heikinheimo M, Anttonen M 2008 GATA-4 regulates Bcl-2 expression in ovarian granulosa cell tumors. Endocrinology 149:5635-5642
28. Samant RS, Shevde LA 2011 Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2:122-134
29. Li L, Wang L, Zhang W, Tang B, Zhang J, Song H, Yao D, Tang Y, Chen X, Yang Z, Wang G, Li X, Zhao J, Ding H, Reed E, Li QQ 2004 Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res 24:1973-1979 (Pubitemid 38954620)
30. Schuppan D, Cramer T, Bauer M, Strefeld T, Hahn EG, Herbst H 1998 Hepatocytes as a source of collagen type XVIII endostatin. Lancet 352:879-880 (Pubitemid 28416727)
31. Feldman AL, Tamarkin L, Paciotti GF, Simpson BW, Linehan WM, Yang JC, Fogler WE, Turner EM, Alexander Jr HR, Libutti SK 2000 Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 6:4628-4634 (Pubitemid 32110397)
32. Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT 1993 Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 90:7533-7537 (Pubitemid 23249984)
33. Koukourakis MI, Limberis V, Tentes I, Kontomanolis E, Kortsaris A, Sivridis E, Giatromanolaki A 2011 Serum VEGF levels and tissue activation of VEGFR2/KDR receptors in patients with breast and gynecologic cancer. Cytokine 53:370-375
34. Feng Y, Venema VJ, Venema RC, Tsai N, Caldwell RB 1999 VEGF induces nuclear translocation of Flk-1/KDR, endothelial nitric oxide synthase, and caveolin-1 in vascular endothelial cells. Biochem Biophys Res Commun 256:192-197 (Pubitemid 29298939)
35. Blazquez C, Cook N, Micklem K, Harris AL, Gatter KC, Pezzella F 2006 Phosphorylated KDR can be located in the nucleus of neoplastic cells. Cell Res 16:93-98 (Pubitemid 43129313)
36. Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, Turley H, Harris AL, Ziche M, Bicknell R 2000 The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 83:63-68 (Pubitemid 30352718)
37. Fan F, Samuel S, Gaur P, Lu J, Dallas NA, Xia L, Bose D, Ramachandran V, Ellis LM 2011 Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer 104:1270-1277
38. Hasan MR, Ho SH, Owen D, Tai IT 26 May 2011 VEGF inhibitors induce cellular senescence in colorectal cancer cells. Int J Cancer 10.1002/ijc.26179
39. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein Jr G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A 2005 Phase I/II trial evaluating the antivascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:2544-2555
40. Tanyi JL, McCann G, Hagemann AR, Coukos G, Rubin SC, Liao JB, Chu CS 2011 Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol 120:464-469